As demonstrated in cell line and patient sample studies, treatment with the TBK1/IKKε inhibitor DMX3433 attenuated canonical NF-κB signaling and decreased DLBCL cell viability [224]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.